Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Merus

Request full access

Antibody engineering to battle cancer

Utrecht, NetherlandsFounded 2003Biotech & Life Sciences

About Merus

Merus N.V. is a clinical-stage oncology company specializing in the development of innovative, full-length multispecific antibodies known as Biclonics®. These bispecific antibody therapeutics are engineered to harness the immune system to target and eliminate cancer cells, offering more effective treatments with fewer side effects. The company operates in the biotechnology sector, primarily serving patients battling cancer. Merus collaborates with other life sciences companies, such as Caris Life Sciences, to enhance patient identification and enrollment for clinical trials, including the Zenocutuzumab Phase 1/2 eNRGy trial. The business model focuses on research and development, clinical trials, and partnerships to bring their therapeutic solutions to market. Revenue is generated through collaborations, licensing agreements, and potential future sales of approved therapies.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2016

Merus in the Utrecht ecosystem

Live from Dealroom

The Merus office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • EQT Life Sciences
  • Novartis Venture Fund
  • Bay City Capital
  • Pfizer
  • Aglaia BioMedical Ventures
  • Johnson & Johnson Development Corporation

Series B and later2 investors entered at this stage

Employees mapped 228 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 8 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$170M

101 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Merus on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.